Leading Analyst Raises Price Targets For This Biotech Company

Cantor Fitzgerald Maintains Overweight on Taysha Gene Therapies, Raises Price Target to $7.

Cantor Fitzgerald, a leading global financial services firm, has reiterated its Overweight rating on Taysha Gene Therapies (NASDAQ: TSHA) and increased the price target to $7, marking an optimistic outlook for the biotech company. The firm's analysis reveals confidence in Taysha's potential, which is focused on developing gene therapies for monogenic di…